AKT1 and Hyperglycemia: Mechanistically, EC alleviated hyperglycemia, insulin resistance, and lipid metabolism abnormalities by protecting the intestinal barrier, modulating the intestinal microbiota, increasing the content of SCFAs, and regulating the profile of BAs, thereby activating intestinal FXR/FGF15 and hepatic PI3K/AKT signaling pathways.